Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

N/A

1(33.3%)

Phase 1

1(33.3%)

Phase 2

1(33.3%)

3Total

N/A(1)

Phase 1(1)

Phase 2(1)

Loading network data...

Showing 5 of 5 trials

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Role: collaborator

High-Strength Suture vs. Traditional Tension Band for Patellar Fractures

Role: lead

Research on Early Diagnosis and Risk Stratification Biomarkers of Anti-Tumor Drug-Associated Interstitial Pneumonia Driven by Multi-Omics Integration

Role: lead

Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

Role: collaborator

Preoperative Rehabilitation Training and Total Knee Arthroplasty Outcomes

Role: lead

All 5 trials loaded